Among them, DC vaccines may elicit and improve antitumor T cell immunity.35 36 Wculek et al found that dead tumor antigen activates DCs ex vivo, and on adoptive transfer in vivo, these DCs induce strong CD8+ T cell responses through antigen cross-presentation and halt the progression of engrafted cancer models. The gene discussed is CD8A; the disease is cancer.